search
Back to results

Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon

Primary Purpose

Huntington's Disease, Parkinson's Disease, Dementia With Lewy Bodies

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ramelteon
Placebo
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Huntington's Disease focused on measuring Huntington's chorea, Huntington's Disease, Parkinson's Disease, Parkinsonism, Dementia, Dementia with Lewy Bodies, Actigraphy, Circadian dysregulation, Sleep Disorders, Circadian rhythm

Eligibility Criteria

20 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

We will recruit 24 Huntington's disease, Parkinson's Disease, or Dementia with Lewy Bodies subjects. Assuming a dropout rate of 20%, we expect that 20 of the 24 subjects who initially enroll will complete the study.

Inclusion criteria will be the following:

  • Subjects with HD will be between the ages of 20 and 65 years old;
  • Subjects with PD or DLB will be between the ages of 40 and 90;
  • Subjects will have subjective complaints of sleeping problems or their caregivers will complain of the subjects not sleeping well
  • Subjects with all severity of HD, PD, and DLB symptoms will be accepted as long as they complain of sleep problems
  • A diagnosis of HD, PD, or DLB. For HD patients, a positive HD gene status for everyone except the caregivers will have been obtained for clinical reasons and will be known at the time of enrollment into the study. PD patients will have a clinical diagnosis of PD. DLB patients will have a diagnosis of possible or probably DLB based on consensus criteria (outlined in McKeith et al., 2005).
  • Subjects will be willing and able to participate in the informed consent process.

Exclusion criteria will be the following:

  • Subjects who are unable to participate in the informed consent process
  • Subjects with previously documented primary sleep disorders (unrelated to HD, PD, or DLB), including Obstructive Sleep Apnea Syndrome, Periodic Limb Movement Disorder of Sleep, or Narcolepsy.
  • Subjects taking fluvoxamine, rifampin, ketoconazole , and fluconazole within 30 days of baseline
  • Subjects with hepatic impairment
  • Subjects who perform shift work or have any other circadian rhythm abnormality or disruption
  • Subjects who are diagnosed with a Major Depressive Episode, current at the time of enrollment (subject may have a history of a Major Depressive Episode as long as it is in partial or full remission at the time of enrollment)
  • Subjects who are diagnosed with a manic or hypomanic episode, current at the time of enrollment (subject may have a history of a manic or hypomanic episode as long as it is in full remission at the time of enrollment)
  • Subjects who at the time of enrollment receive hypnotic agents or have been on hypnotic agents during the two weeks prior to enrollment
  • Subjects who are pregnant at the time of enrollment or intend to become pregnant during the period of study participation
  • Subjects who in the opinion of the research personnel would not be able to participate in the research protocol because of agitation, lack of transportation, or other reasons.

Sites / Locations

  • Massachusetts General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Ramelteon

Placebo

Arm Description

Subjects randomized to Ramelteon

Subjects randomized to placebo

Outcomes

Primary Outcome Measures

Sleep efficiency and other actigraphy derived sleep parameters

Secondary Outcome Measures

UHDRS, UPDRS, cognitive measures, mood symptoms, aggression measures, functional ability.

Full Information

First Posted
May 20, 2009
Last Updated
November 2, 2012
Sponsor
Massachusetts General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT00907595
Brief Title
Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon
Official Title
Treating Sleep Wake Cycle Disturbances in Basal Ganglia Neurodegenerative Disorder Subjects With Ramelteon- A Double Blind, Placebo Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2012
Overall Recruitment Status
Withdrawn
Why Stopped
unable to recruit subjects for study.Collaborator stopped funding for study as of 3/31/2010
Study Start Date
May 2009 (undefined)
Primary Completion Date
March 2010 (Actual)
Study Completion Date
July 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The proposed study is a double-blind, placebo controlled pilot study of HD, PD, and DLB subjects with sleep disturbances. This study is designed to determine the effects of 4 weeks Ramelteon treatment on the sleep patterns of people with basal ganglia disorders such as HD, PD and DLB. The study also aims to look at the sleep patterns of caregivers of people with HD, PD and DLB.
Detailed Description
Huntington's disease (HD) is a progressively degenerative brain disorder, which results in a loss of mental and physical abilities. It is genetically determined and people carrying the HD gene invariably develop the clinical disorder at some point in their lives. HD symptoms consist of neuropsychiatric changes and motor movements. Once present, the symptoms are progressive in nature and eventually fatal. Currently there is no cure for HD. Like HD, Parkinson's Disease (PD) and Dementia with Lewy Bodies (DLB) are also neurodegenerative disorders affecting the basal ganglia. PD and DLB are synucleinopathies - i.e., they are associated with dysfunction of the protein alpha-synuclein. Unlike HD, PD and DLB are not inherited in an autosomal dominant manner. Sleep/wake cycles in HD, PD and DLB. HD patients, especially those in moderate to severe stages of the disease, frequently complain of difficulty falling and staying asleep. Little is known about the phenomenology and pathophysiology of sleep disturbances in HD. The few studies that have addressed this issue of sleep in HD have found disturbances in sleep architecture and sleep/wake cycles. Overall, the literature on sleep and other circadian disturbances in HD is very limited. If sleep/wake cycle disturbances in HD have pathophysiological mechanisms similar to other neurodegenerative disorders, then Ramelteon, a hypnotic agent and melatonin receptor agonist, may be beneficial in sleep/wake cycle disturbances in HD. Sleep disruptions and circadian sleep disruptions are integral to the clinical presentation of both PD and DLB. As is true in HD, sleep disturbances in PD and DLB cause severe disruption to the patients and their caregivers' lives. In PD, sleep dysfunction occurs in approximately two thirds of patients. Sleep problems range from difficulty with sleep initiation, sleep fragmentation, disturbance of circadian rhythm, REM sleep behavior disorder (RBD), to excessive daytime sleepiness. Frequent nighttime awakening and sleep disruption are the most common sleep problems in PD. In DLB, REM sleep behavior disorder (RBD) occurs years to decades before the onset of dementia. Importantly, melatonin is one of the main treatments used for RBD. Therefore, a melatonin agonist such as Ramelteon is a natural choice for the treatment of circadian sleep disturbances in PD and DLB. Activity monitors (actigraphs) have been used as an alternative to polysomnography (PSG). Actigraphs are small electronic motion sensors that detect movements in three axes and provide information about the subjects' activity levels over periods of days to weeks. Using validated algorithms to infer wakefulness and sleep, investigators can draw conclusions about the individuals' sleep/wake cycle patterns from their activity patterns.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Huntington's Disease, Parkinson's Disease, Dementia With Lewy Bodies, Sleep Disorders, Circadian Dysregulation
Keywords
Huntington's chorea, Huntington's Disease, Parkinson's Disease, Parkinsonism, Dementia, Dementia with Lewy Bodies, Actigraphy, Circadian dysregulation, Sleep Disorders, Circadian rhythm

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ramelteon
Arm Type
Active Comparator
Arm Description
Subjects randomized to Ramelteon
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects randomized to placebo
Intervention Type
Drug
Intervention Name(s)
Ramelteon
Intervention Description
After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
Primary Outcome Measure Information:
Title
Sleep efficiency and other actigraphy derived sleep parameters
Time Frame
2 weeks pre intervention; 4 weeks of the intervention; 2 weeks after intervention
Secondary Outcome Measure Information:
Title
UHDRS, UPDRS, cognitive measures, mood symptoms, aggression measures, functional ability.
Time Frame
2 weeks pre intervention; 4 weeks of the intervention; 2 weeks after intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
We will recruit 24 Huntington's disease, Parkinson's Disease, or Dementia with Lewy Bodies subjects. Assuming a dropout rate of 20%, we expect that 20 of the 24 subjects who initially enroll will complete the study. Inclusion criteria will be the following: Subjects with HD will be between the ages of 20 and 65 years old; Subjects with PD or DLB will be between the ages of 40 and 90; Subjects will have subjective complaints of sleeping problems or their caregivers will complain of the subjects not sleeping well Subjects with all severity of HD, PD, and DLB symptoms will be accepted as long as they complain of sleep problems A diagnosis of HD, PD, or DLB. For HD patients, a positive HD gene status for everyone except the caregivers will have been obtained for clinical reasons and will be known at the time of enrollment into the study. PD patients will have a clinical diagnosis of PD. DLB patients will have a diagnosis of possible or probably DLB based on consensus criteria (outlined in McKeith et al., 2005). Subjects will be willing and able to participate in the informed consent process. Exclusion criteria will be the following: Subjects who are unable to participate in the informed consent process Subjects with previously documented primary sleep disorders (unrelated to HD, PD, or DLB), including Obstructive Sleep Apnea Syndrome, Periodic Limb Movement Disorder of Sleep, or Narcolepsy. Subjects taking fluvoxamine, rifampin, ketoconazole , and fluconazole within 30 days of baseline Subjects with hepatic impairment Subjects who perform shift work or have any other circadian rhythm abnormality or disruption Subjects who are diagnosed with a Major Depressive Episode, current at the time of enrollment (subject may have a history of a Major Depressive Episode as long as it is in partial or full remission at the time of enrollment) Subjects who are diagnosed with a manic or hypomanic episode, current at the time of enrollment (subject may have a history of a manic or hypomanic episode as long as it is in full remission at the time of enrollment) Subjects who at the time of enrollment receive hypnotic agents or have been on hypnotic agents during the two weeks prior to enrollment Subjects who are pregnant at the time of enrollment or intend to become pregnant during the period of study participation Subjects who in the opinion of the research personnel would not be able to participate in the research protocol because of agitation, lack of transportation, or other reasons.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kaloyan S Tanev, MD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02144
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
15742112
Citation
Hurelbrink CB, Lewis SJ, Barker RA. The use of the Actiwatch-Neurologica system to objectively assess the involuntary movements and sleep-wake activity in patients with mild-moderate Huntington's disease. J Neurol. 2005 Jun;252(6):642-7. doi: 10.1007/s00415-005-0709-z. Epub 2005 Mar 7.
Results Reference
background
PubMed Identifier
15634777
Citation
Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci. 2005 Jan 5;25(1):157-63. doi: 10.1523/JNEUROSCI.3842-04.2005. Erratum In: J Neurosci. 2005 Apr 13;25(15):3994.
Results Reference
background
PubMed Identifier
9130330
Citation
Ancoli-Israel S, Clopton P, Klauber MR, Fell R, Mason W. Use of wrist activity for monitoring sleep/wake in demented nursing-home patients. Sleep. 1997 Jan;20(1):24-7. doi: 10.1093/sleep/20.1.24.
Results Reference
background

Learn more about this trial

Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon

We'll reach out to this number within 24 hrs